Search

Purpose: Although currently rare due to more accurate preoperative evaluations and modern surgical techniques, iatrogenic ectasia remains a complication after refractive surgery. Small Incision Lenticule Extraction (SMILE) and photorefractive keratectomy (PRK) are superior in preserving corneal biomechanics[for full text, please go to the a.m. URL], 34. Kongress der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation, interventionelle und refraktive Chirurgie

In diesem Referat stelle ich unsere Arbeiten der letzten 3 Jahre über die Biomechanik der menschlichen Hornhaut nach Myopie-Behandlung. Getestet wurden paarige Hornhäute verstorbener ex-vivo mittels 2D-Extensiometrie. Gegeneinander getestet wurden Femto-Lasik, PRK und SMILE. Darüber hinaus[zum vollständigen Text gelangen Sie über die oben angegebene URL], 92. Versammlung des Vereins Rhein-Mainischer Augenärzte

Purpose: To investigate the biomechanical properties of the ex vivo human cornea after photorefractive keratektomy versus lenticle extraction refractive surgery in the same donor. Setting/venue: In this experimental study, 13 pairs of human corneas unsuitable for transplantation were equally[for full text, please go to the a.m. URL], 33. Kongress der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie (DGII)

Corneal cross-linking (CXL), introduced by Wollensak et al. in 2003, is a minimally invasive procedure to halt the progression of keratoconus. Conventional CXL is recommended in eyes with corneal thickness of at least 400 microns after de-epithelialization to prevent endothelial toxicity. However, most of the keratoconic corneas requiring CXL may not fulfill this preoperative inclusion criterion. Moderate-to-advanced cases are often found to have a pachymetry less than this threshold. There are various modifications to the conventional method to circumvent this issue of CXL thin corneas while avoiding the possible complications. This review is an update on the modifications of conventional CXL for thin corneas.

Corneal cross-linking (CXL), introduced by Wollensak et al. in 2003, is a minimally invasive procedure to halt the progression of keratoconus. Conventional CXL is recommended in eyes with corneal thickness of at least 400 microns after de-epithelialization to prevent endothelial toxicity. However, most of the keratoconic corneas requiring CXL may not fulfill this preoperative inclusion criterion. Moderate-to-advanced cases are often found to have a pachymetry less than this threshold. There are various modifications to the conventional method to circumvent this issue of CXL thin corneas while avoiding the possible complications. This review is an update on the modifications of conventional CXL for thin cornea.s. © 2018 Indian Journal of Ophthalmology Published by Wolters Kluwer - Medknow.

Ziele: Ein Update über den aktuellen Stand der Forschung und Klinik bezüglich PACK Cross-Linking (photoactivated promo for the treatment of keratitis) geben Aufzeigen, welche Resultate die klinische Anwendung unterstützen. Methode: Der Vortrag wird einen Überblick über[zum vollständigen Text gelangen Sie über die oben angegebene URL], 31. Internationaler Kongress der Deutschen Ophthalmochirurgen

Purpose: To investigate the biomechanical properties of the ex-vivo human cornea after flap-based vs. cap-based laser refractive surgery in the same donor. Design: Experimental study Methods: 11 pairs of human corneas were equally divided into 2 groups: Corneas from right eye were treated with[for full text, please go to the a.m. URL], 32. Kongress der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie (DGII)

Purpose: To determine the corneal weakening induced by different re-treatment options after SmILE, and to investigate the potential of corneal cross-linking (CXL) to re-establish the original corneal stress resistance. Methods: A total of 96 freshly enucleated porcine corneas were used. The initial[for full text, please go to the a.m. URL], 31. Kongress der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation, Interventionelle und Refraktive Chirurgie (DGII)

Background: Since the late 1990s corneal crosslinking (CXL) has been proposed as a new treatment option which can stop progression of keratoconus with promising results in adults. Objective: Keratoconus presents a higher rate and faster progression in paediatric patients and for this reason prompt and effective treatment is essential. Due to its success in adult keratoconus patients, CXL has been recently applied to children in order to stop or slow progression of keratoconus in paediatric patients. Conclusions: This article will present an update of the literature on the topic of CXL in this age group. © 2017 Panos et al.

© 2015 American Academy of Ophthalmology. Purpose: Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this clinical trial was to evaluate the safety, reliability, and benefit of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) in restoring some visual function to subjects completely blind from RP. We report clinical trial results at 1 and 3 years after implantation. Design: The study is a multicenter, single-arm, prospective clinical trial. Participants: There were 30 subjects in 10 centers in the United States and Europe. Subjects served as their own controls, that is, implanted eye versus fellow eye, and system on versus system off (native residual vision). Methods: The Argus II System was implanted on and in a single eye (typically the worse-seeing eye) of blind subjects. Subjects wore glasses mounted with a small camera and a video processor that converted images into stimulation patterns sent to the electrode array on the retina. Main Outcome Measures: The primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests. Results: A total of 29 of 30 subjects had functioning Argus II Systems implants 3 years after implantation. Eleven subjects experienced a total of 23 serious device- or surgery-related adverse events. All were treated with standard ophthalmic care. As a group, subjects performed significantly better with the system on than off on all visual function tests and functional vision assessments. Conclusions: The 3-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind from RP. Earlier results from this trial were used to gain approval of the Argus II by the Food and Drug Administration and a CE mark in Europe. The Argus II System is the first and only retinal implant to have both approvals.

Purpose: The Argus II clinical trial is the largest trial of a retinal prosthesis in the world. Its subjects are constantly followed for safety and performance. There are 10 implanting centers involved in the clinical trial in the US, UK, France, and Switzerland. Before implantation, all 30 subjects[for full text, please go to the a.m. URL], 27. Internationaler Kongress der Deutschen Ophthalmochirurgen